来曲唑联合控制性卵巢过度刺激与传统方案在乳腺癌患者生育力保存中的疗效与安全性:多中心回顾性研究
该多中心回顾性研究比较了97例≤40岁非转移性乳腺癌患者采用来曲唑联合控制性卵巢过度刺激(LetCOH)或传统方案(cCOH)进行生育力保存的结局。LetCOH组卵母细胞成熟率显著更高(p<0.001),雌二醇峰值更低,采集成熟卵母细胞最终数量未受影响。中位随访四年,两组复发与死亡例数相近,LetCOH与cCOH同样有效,但需更长随访。
要点
- LetCOH组卵母细胞成熟率显著高于cCOH组(p<0.001),成熟卵母细胞最终采集数未受影响。
- LetCOH组排卵触发时雌二醇峰值低于cCOH组。
- 中位随访四年,LetCOH组7例、cCOH组4例复发,两组各1例死亡。
核心结论
- LetCOH在生育力保存中与cCOH同样有效。
- 目前未发现cCOH在辅助治疗背景下的安全性问题,但需要更长随访。
研究设计与样本
- 多中心回顾性研究,纳入2012年12月至2017年1月在CHU-Lille和Erasme医院接受生育力保存的97例≤40岁非转移性乳腺癌患者,共107个周期。
- cCOH组56个周期,LetCOH组41个周期。
主要发现
- 除肿瘤大小和HER2状态外,两组患者及肿瘤特征相似,LetCOH组肿瘤大小和HER2状态更不利。
- cCOH组和LetCOH组分别有96.4%和48.8%的患者接受辅助化疗,LetCOH组51.2%接受新辅助化疗(p<0.001)。
- LetCOH组排卵触发时雌二醇峰值低于cCOH组。
- LetCOH组卵母细胞成熟率显著高于cCOH组(p<0.001),成熟卵母细胞最终采集数未受影响。
- 中位随访四年,LetCOH组7例、cCOH组4例复发,两组各1例死亡。
局限性
- 原文指出需要更长随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Fertility preservation (FP) is recommended in young breast cancer (BC) patients before (neo)adjuvant treatment. Letrozole-associated controlled ovarian hyperstimulation (LetCOH) is used worldwide to collect mature oocytes for FP, but its efficacy and safety compared to conventional protocols (cCOH) are still debated. AIMS: To compare efficacy and safety of FP procedure using LetCOH or cCOH in BC patients in terms of oocyte maturation rate and disease-free survival rates after at least two years of follow-up. METHODS: This multicenter retrospective study compared outcomes of 107 cycles in 97 non-metastatic BC patients aged ≤40 years who underwent cCOH (n = 56) or LetCOH (n = 41) for FP in CHU-Lille and Erasme Hospital, respectively, between December 2012 and January 2017. RESULTS: Patients and oncological characteristics were similar except for tumor size and HER2 status which were less favorable in the LetCOH group. Patients underwent adjuvant chemotherapy in 96.4% and 48.8% of the cases in cCOH and LetCOH groups, respectively. Hence, 51.2% of LetCOH patients underwent neoadjuvant chemotherapy (p < 0.001). Estradiol peak at ovulation trigger was lower in LetCOH compared to cCOH group while oocyte maturation rates were significantly higher (p < 0.001), without impacting the final number of mature oocytes collected. Seven and four patients relapsed in LetCOH and cCOH groups, respectively, and one patient died in each group after a median follow-up of four years. CONCLUSION: LetCOH is as effective as cCOH for FP. At this time point, there were no safety concerns regarding cCOH in the adjuvant setting but a longer follow-up is warranted.
引用
- Goldrat O, De Cooman M, Mailliez A, et al. Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study. Eur J Cancer. 2022. PMID: 35998549. doi:10.1016/j.ejca.2022.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。